Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19
With the persistent COVID-19 pandemic, there is an urgent need to use rapid and reliable diagnostic tools for highly urgent cases. Antigen tests are disappointing with their lack of sensitivity. Among molecular tools allowing a diagnosis in less than an hour, only one, the Cepheid Xpert Xpress SARS-...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2020-12, Vol.133, p.104682-104682, Article 104682 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104682 |
|---|---|
| container_issue | |
| container_start_page | 104682 |
| container_title | Journal of clinical virology |
| container_volume | 133 |
| creator | Fournier, Pierre-Edouard Zandotti, Christine Ninove, Laetitia Prudent, Elsa Colson, Philippe Gazin, Céline Million, Matthieu Tissot-Dupont, Hervé Fenollar, Florence |
| description | With the persistent COVID-19 pandemic, there is an urgent need to use rapid and reliable diagnostic tools for highly urgent cases. Antigen tests are disappointing with their lack of sensitivity. Among molecular tools allowing a diagnosis in less than an hour, only one, the Cepheid Xpert Xpress SARS-CoV-2 assay, has exhibited a good sensitivity. However, we are also facing a global shortage of reagents and kits. Thus, it is imperative to evaluate other point-of-care molecular tests.
We evaluated the VitaPCR™ RT-PCR assay, whose sample analysis time is of approximately 20 min, in nasopharyngeal secretions from 534 patients presenting to our Institute, for the diagnosis of COVID-19, and compared it to our routine RT-PCR assay. We also compared the two assays with tenfold dilutions of a SARS-CoV-2 strain.
Compared to our routine RT-PCR and the previous diagnosis of COVID-19, the sensitivity, specificity, positive and negative predictive values of VitaPCR™ can be evaluated to be 99.3 % (155/156), 94.7 % (358/378), 88.6 % (155/175) and 99.7 % (358/359), respectively. Tenfold dilutions of a SARS-CoV-2 strain show that the VitaPCR™ was more sensitive that our routine RT-PCR assay.
The VitaPCR™ SARS-CoV-2 is an accurate rapid test, suitable for clinical practice that can be performed as part of a point-of-care testing, for the rapid diagnosis of COVID-19. |
| doi_str_mv | 10.1016/j.jcv.2020.104682 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7598902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1386653220304248</els_id><sourcerecordid>2458037372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-5053fc4221239eaf56dd78621076ca863b0438ae00932b64afb89b1ea4358dd3</originalsourceid><addsrcrecordid>eNp9kVtP2zAYhq0JNE77AbuZcskuUnyOo0lIVTagUiUQoN5ajvOlddXGYKeV-PdzFEAbF1zFsd_38eFB6DvBE4KJvFhP1nY_oZgO_1wq-gUdE1WwXJSyOEhjpmQuBaNH6CTGNcZEMF58RUeMEUGllMdoVvmuD67e9c53mW-zhevNXXWfPUzvH_LKL3Ka9T7rV5DBFsISOvuSNc4sOx9dHArV7WL2OyflGTpszSbCt9fvKXq8-vNY3eTz2-tZNZ3nlivR5wIL1lpOKaGsBNMK2TSFkpTgQlqjJKsxZ8oAxiWjteSmrVVZEzCcCdU07BRdjtinXb2FxkI6vtnop-C2Jrxob5z-f6VzK730e12IUpWYJsDPEbD6ULuZzvUwhxnhJWV8T1L2_HWz4J93EHu9ddHCZmM68LuoKRcKs4IVA5aMURt8jAHadzbBerCl1zrZ0oMtPdpKnR__3uW98aYnBX6NAUgPuncQdLQuKYDGBbC9brz7BP8XEsGiGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458037372</pqid></control><display><type>article</type><title>Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fournier, Pierre-Edouard ; Zandotti, Christine ; Ninove, Laetitia ; Prudent, Elsa ; Colson, Philippe ; Gazin, Céline ; Million, Matthieu ; Tissot-Dupont, Hervé ; Fenollar, Florence</creator><creatorcontrib>Fournier, Pierre-Edouard ; Zandotti, Christine ; Ninove, Laetitia ; Prudent, Elsa ; Colson, Philippe ; Gazin, Céline ; Million, Matthieu ; Tissot-Dupont, Hervé ; Fenollar, Florence</creatorcontrib><description>With the persistent COVID-19 pandemic, there is an urgent need to use rapid and reliable diagnostic tools for highly urgent cases. Antigen tests are disappointing with their lack of sensitivity. Among molecular tools allowing a diagnosis in less than an hour, only one, the Cepheid Xpert Xpress SARS-CoV-2 assay, has exhibited a good sensitivity. However, we are also facing a global shortage of reagents and kits. Thus, it is imperative to evaluate other point-of-care molecular tests.
We evaluated the VitaPCR™ RT-PCR assay, whose sample analysis time is of approximately 20 min, in nasopharyngeal secretions from 534 patients presenting to our Institute, for the diagnosis of COVID-19, and compared it to our routine RT-PCR assay. We also compared the two assays with tenfold dilutions of a SARS-CoV-2 strain.
Compared to our routine RT-PCR and the previous diagnosis of COVID-19, the sensitivity, specificity, positive and negative predictive values of VitaPCR™ can be evaluated to be 99.3 % (155/156), 94.7 % (358/378), 88.6 % (155/175) and 99.7 % (358/359), respectively. Tenfold dilutions of a SARS-CoV-2 strain show that the VitaPCR™ was more sensitive that our routine RT-PCR assay.
The VitaPCR™ SARS-CoV-2 is an accurate rapid test, suitable for clinical practice that can be performed as part of a point-of-care testing, for the rapid diagnosis of COVID-19.</description><identifier>ISSN: 1386-6532</identifier><identifier>ISSN: 1873-5967</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2020.104682</identifier><identifier>PMID: 33152666</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 Nucleic Acid Testing ; Diagnosis ; Emergency Medical Services ; Female ; Humans ; Life Sciences ; Male ; Middle Aged ; Nasopharynx - virology ; Point-of-care ; Point-of-Care Testing ; Predictive Value of Tests ; Rapid diagnostic test ; SARS-CoV-2 ; SARS-CoV-2 - genetics ; Sensitivity and Specificity ; Short Communication ; Time Factors ; Young Adult</subject><ispartof>Journal of clinical virology, 2020-12, Vol.133, p.104682-104682, Article 104682</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-5053fc4221239eaf56dd78621076ca863b0438ae00932b64afb89b1ea4358dd3</citedby><cites>FETCH-LOGICAL-c485t-5053fc4221239eaf56dd78621076ca863b0438ae00932b64afb89b1ea4358dd3</cites><orcidid>0000-0002-9456-4012 ; 0000-0002-7517-0173 ; 0000-0001-8463-8885 ; 0000-0002-5556-6947 ; 0000-0001-6285-0308</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcv.2020.104682$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33152666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-03149234$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Fournier, Pierre-Edouard</creatorcontrib><creatorcontrib>Zandotti, Christine</creatorcontrib><creatorcontrib>Ninove, Laetitia</creatorcontrib><creatorcontrib>Prudent, Elsa</creatorcontrib><creatorcontrib>Colson, Philippe</creatorcontrib><creatorcontrib>Gazin, Céline</creatorcontrib><creatorcontrib>Million, Matthieu</creatorcontrib><creatorcontrib>Tissot-Dupont, Hervé</creatorcontrib><creatorcontrib>Fenollar, Florence</creatorcontrib><title>Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>With the persistent COVID-19 pandemic, there is an urgent need to use rapid and reliable diagnostic tools for highly urgent cases. Antigen tests are disappointing with their lack of sensitivity. Among molecular tools allowing a diagnosis in less than an hour, only one, the Cepheid Xpert Xpress SARS-CoV-2 assay, has exhibited a good sensitivity. However, we are also facing a global shortage of reagents and kits. Thus, it is imperative to evaluate other point-of-care molecular tests.
We evaluated the VitaPCR™ RT-PCR assay, whose sample analysis time is of approximately 20 min, in nasopharyngeal secretions from 534 patients presenting to our Institute, for the diagnosis of COVID-19, and compared it to our routine RT-PCR assay. We also compared the two assays with tenfold dilutions of a SARS-CoV-2 strain.
Compared to our routine RT-PCR and the previous diagnosis of COVID-19, the sensitivity, specificity, positive and negative predictive values of VitaPCR™ can be evaluated to be 99.3 % (155/156), 94.7 % (358/378), 88.6 % (155/175) and 99.7 % (358/359), respectively. Tenfold dilutions of a SARS-CoV-2 strain show that the VitaPCR™ was more sensitive that our routine RT-PCR assay.
The VitaPCR™ SARS-CoV-2 is an accurate rapid test, suitable for clinical practice that can be performed as part of a point-of-care testing, for the rapid diagnosis of COVID-19.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 Nucleic Acid Testing</subject><subject>Diagnosis</subject><subject>Emergency Medical Services</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasopharynx - virology</subject><subject>Point-of-care</subject><subject>Point-of-Care Testing</subject><subject>Predictive Value of Tests</subject><subject>Rapid diagnostic test</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - genetics</subject><subject>Sensitivity and Specificity</subject><subject>Short Communication</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>1386-6532</issn><issn>1873-5967</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVtP2zAYhq0JNE77AbuZcskuUnyOo0lIVTagUiUQoN5ajvOlddXGYKeV-PdzFEAbF1zFsd_38eFB6DvBE4KJvFhP1nY_oZgO_1wq-gUdE1WwXJSyOEhjpmQuBaNH6CTGNcZEMF58RUeMEUGllMdoVvmuD67e9c53mW-zhevNXXWfPUzvH_LKL3Ka9T7rV5DBFsISOvuSNc4sOx9dHArV7WL2OyflGTpszSbCt9fvKXq8-vNY3eTz2-tZNZ3nlivR5wIL1lpOKaGsBNMK2TSFkpTgQlqjJKsxZ8oAxiWjteSmrVVZEzCcCdU07BRdjtinXb2FxkI6vtnop-C2Jrxob5z-f6VzK730e12IUpWYJsDPEbD6ULuZzvUwhxnhJWV8T1L2_HWz4J93EHu9ddHCZmM68LuoKRcKs4IVA5aMURt8jAHadzbBerCl1zrZ0oMtPdpKnR__3uW98aYnBX6NAUgPuncQdLQuKYDGBbC9brz7BP8XEsGiGg</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Fournier, Pierre-Edouard</creator><creator>Zandotti, Christine</creator><creator>Ninove, Laetitia</creator><creator>Prudent, Elsa</creator><creator>Colson, Philippe</creator><creator>Gazin, Céline</creator><creator>Million, Matthieu</creator><creator>Tissot-Dupont, Hervé</creator><creator>Fenollar, Florence</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9456-4012</orcidid><orcidid>https://orcid.org/0000-0002-7517-0173</orcidid><orcidid>https://orcid.org/0000-0001-8463-8885</orcidid><orcidid>https://orcid.org/0000-0002-5556-6947</orcidid><orcidid>https://orcid.org/0000-0001-6285-0308</orcidid></search><sort><creationdate>20201201</creationdate><title>Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19</title><author>Fournier, Pierre-Edouard ; Zandotti, Christine ; Ninove, Laetitia ; Prudent, Elsa ; Colson, Philippe ; Gazin, Céline ; Million, Matthieu ; Tissot-Dupont, Hervé ; Fenollar, Florence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-5053fc4221239eaf56dd78621076ca863b0438ae00932b64afb89b1ea4358dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 Nucleic Acid Testing</topic><topic>Diagnosis</topic><topic>Emergency Medical Services</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasopharynx - virology</topic><topic>Point-of-care</topic><topic>Point-of-Care Testing</topic><topic>Predictive Value of Tests</topic><topic>Rapid diagnostic test</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - genetics</topic><topic>Sensitivity and Specificity</topic><topic>Short Communication</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fournier, Pierre-Edouard</creatorcontrib><creatorcontrib>Zandotti, Christine</creatorcontrib><creatorcontrib>Ninove, Laetitia</creatorcontrib><creatorcontrib>Prudent, Elsa</creatorcontrib><creatorcontrib>Colson, Philippe</creatorcontrib><creatorcontrib>Gazin, Céline</creatorcontrib><creatorcontrib>Million, Matthieu</creatorcontrib><creatorcontrib>Tissot-Dupont, Hervé</creatorcontrib><creatorcontrib>Fenollar, Florence</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fournier, Pierre-Edouard</au><au>Zandotti, Christine</au><au>Ninove, Laetitia</au><au>Prudent, Elsa</au><au>Colson, Philippe</au><au>Gazin, Céline</au><au>Million, Matthieu</au><au>Tissot-Dupont, Hervé</au><au>Fenollar, Florence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>133</volume><spage>104682</spage><epage>104682</epage><pages>104682-104682</pages><artnum>104682</artnum><issn>1386-6532</issn><issn>1873-5967</issn><eissn>1873-5967</eissn><abstract>With the persistent COVID-19 pandemic, there is an urgent need to use rapid and reliable diagnostic tools for highly urgent cases. Antigen tests are disappointing with their lack of sensitivity. Among molecular tools allowing a diagnosis in less than an hour, only one, the Cepheid Xpert Xpress SARS-CoV-2 assay, has exhibited a good sensitivity. However, we are also facing a global shortage of reagents and kits. Thus, it is imperative to evaluate other point-of-care molecular tests.
We evaluated the VitaPCR™ RT-PCR assay, whose sample analysis time is of approximately 20 min, in nasopharyngeal secretions from 534 patients presenting to our Institute, for the diagnosis of COVID-19, and compared it to our routine RT-PCR assay. We also compared the two assays with tenfold dilutions of a SARS-CoV-2 strain.
Compared to our routine RT-PCR and the previous diagnosis of COVID-19, the sensitivity, specificity, positive and negative predictive values of VitaPCR™ can be evaluated to be 99.3 % (155/156), 94.7 % (358/378), 88.6 % (155/175) and 99.7 % (358/359), respectively. Tenfold dilutions of a SARS-CoV-2 strain show that the VitaPCR™ was more sensitive that our routine RT-PCR assay.
The VitaPCR™ SARS-CoV-2 is an accurate rapid test, suitable for clinical practice that can be performed as part of a point-of-care testing, for the rapid diagnosis of COVID-19.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33152666</pmid><doi>10.1016/j.jcv.2020.104682</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9456-4012</orcidid><orcidid>https://orcid.org/0000-0002-7517-0173</orcidid><orcidid>https://orcid.org/0000-0001-8463-8885</orcidid><orcidid>https://orcid.org/0000-0002-5556-6947</orcidid><orcidid>https://orcid.org/0000-0001-6285-0308</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2020-12, Vol.133, p.104682-104682, Article 104682 |
| issn | 1386-6532 1873-5967 1873-5967 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7598902 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over COVID-19 COVID-19 - diagnosis COVID-19 Nucleic Acid Testing Diagnosis Emergency Medical Services Female Humans Life Sciences Male Middle Aged Nasopharynx - virology Point-of-care Point-of-Care Testing Predictive Value of Tests Rapid diagnostic test SARS-CoV-2 SARS-CoV-2 - genetics Sensitivity and Specificity Short Communication Time Factors Young Adult |
| title | Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20VitaPCR%20SARS-CoV-2%20to%20the%20emergency%20diagnosis%20of%20COVID-19&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Fournier,%20Pierre-Edouard&rft.date=2020-12-01&rft.volume=133&rft.spage=104682&rft.epage=104682&rft.pages=104682-104682&rft.artnum=104682&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2020.104682&rft_dat=%3Cproquest_pubme%3E2458037372%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458037372&rft_id=info:pmid/33152666&rft_els_id=S1386653220304248&rfr_iscdi=true |